Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine

Transplantation

Volumn 67, Issue 7, 1999, Pages 1036-1042

  Groth, Carl G ^a   Bäckman, Lars ^b   Morales, José Maria ^c   Calne, Roy ^d   Kreis, Henri ^e   Lang, Philippe ^f   Touraine, Jean Louis ^g   Claesson, Kerstin ^h   Campistol, Josep M ⁱ   Durand, Dominique ^j   Wramner, Lars ^b   Brattström, Christina ^a   Charpentier, Bernard ^k  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j CHU RANGUEIL   (France)

^k BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MAGNESIUM; METHYLPREDNISOLONE; POTASSIUM; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; EUROPE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURVIVAL; THROMBOCYTOPENIA;

ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PATIENT DROPOUTS; PILOT PROJECTS; SIROLIMUS; TREATMENT OUTCOME;

EID: 0345161813     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199904150-00017     Document Type: Article

References (25)

1. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monitor 1995; 17: 660.
2. Liu J, Farmer Jr. JD, Lane C, Friedman J, Weissman I, Schreiber SL, Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK 506 complexes. Cell 1991; 66: 807.
3. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436.
4. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
5. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997; 17: 34.
6. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 59: 183.
7. Fryer J, Yatscoff RW, Pascoe EA, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 1993; 55: 340.
8. DiJoseph JF, Fluhler E, Armstrong J, Sharr M, Sehgal SN. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 1996; 62: 1109.
9. Ryffel B, Car B, Weber E, Mihatsch MJ. Nephrotoxicity of immunosuppressants in rats: comparisons of macrolides with cyclosporine. Exp Nephrol 1994; 2: 324.
10. Golbaekdal K, Nielsen CB, Djurhuus JC, Pederson EB. Effects of rapamycin on renal hemodynamics, water and sodium excretions and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. Transplantation 1994; 58: 1153.
11. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507.
12. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209.
13. Nankivell BD, Gruenwald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
14. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine treated recipients. Transplantation 1996; 62: 1235.
15. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412.
16. Pham SM, Shears LL, Kawahara N, Venkataramanan R, Sehgal S. High local production nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc 1998; 30: 953.
17. Barbosa LM, Gauthier VJ, Davis CL. Bone pain that responds to to calcium channel blockers. Transplantation 1995; 59: 541.
18. Stevens JM, Hilson JW, Sweny P. Post-renal transplant distal limb bone pain. Transplantation 1995; 61: 305.
19. Carmichael DJS, Hamilton DV, Evans DB, Stoven PGI, Calne RY. Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax 1983; 38: 951.
20. Akoun G, Mayaud C, Touboul JL, Gauthier-Rahman S, El Gaharbi N. La pneumopathic d'hypersensibilité à l'azathioprine. Therapie 1986; 41: 73.
21. Brattström C, Wilczek H, Tydén G, Böttiger Y, Säwe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272.
22. Salas-Prato M, Assalian A, Mehdi AZ, Brazeau P et al. Inhibition by rapamycin of PDGF- and bFGF-induced human tendon fibroblast proliferation in vitro. J Glaucoma 1996; 5: 54.
23. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three double-blind, clinical studies in the prevention of rejection. The International Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
24. Roth D, Colona J, Burke GW, Giancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998; 65: 248.
25. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.